GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bellicum Pharmaceuticals Inc (OTCPK:BLCM) » Definitions » Mohanram G-Score

Bellicum Pharmaceuticals (Bellicum Pharmaceuticals) Mohanram G-Score : 1 (As of Sep. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Bellicum Pharmaceuticals Mohanram G-Score?

Mohanram G-Score is a financial indicator developed by professor Partha Mohanram to help investors find the best investment opportunities in the growth stocks. Companies have higher G-score tends to generate higher return. According to his study, the best growth stocks that have a G-Score greater than 6 tend to beat the market, while those with a G-Score lower than 1 tend to have negative absolute returns.

Thus, the zones of discrimination were as such:

Good or high score = 6, 7, 8
Bad or low score = 0, 1

Bellicum Pharmaceuticals has an G-score of 1. It is a bad or low score, which tends to have negative absolute returns.

The historical rank and industry rank for Bellicum Pharmaceuticals's Mohanram G-Score or its related term are showing as below:

BLCM' s Mohanram G-Score Range Over the Past 10 Years
Min: 1   Med: 2   Max: 3
Current: 1

During the past 11 years, the highest Piotroski G-score of Bellicum Pharmaceuticals was 3. The lowest was 1. And the median was 2.


Bellicum Pharmaceuticals Mohanram G-Score Historical Data

The historical data trend for Bellicum Pharmaceuticals's Mohanram G-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellicum Pharmaceuticals Mohanram G-Score Chart

Bellicum Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Mohanram G-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A 3.00 2.00 2.00 1.00

Bellicum Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Mohanram G-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 1.00 2.00 1.00 1.00

Competitive Comparison of Bellicum Pharmaceuticals's Mohanram G-Score

For the Biotechnology subindustry, Bellicum Pharmaceuticals's Mohanram G-Score, along with its competitors' market caps and Mohanram G-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bellicum Pharmaceuticals's Mohanram G-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bellicum Pharmaceuticals's Mohanram G-Score distribution charts can be found below:

* The bar in red indicates where Bellicum Pharmaceuticals's Mohanram G-Score falls into.



Bellicum Pharmaceuticals Mohanram G-Score Calculation

The calculation of the Mohanram G-score consists of eight criteria. Assign one point for each criterion met, then add up all the points to get the G-Score.

Profitability

Question 1. Return on Assets (ROA)

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. It measures how well a company uses its asset to generate earnings.

Score 1 if ROA > ROA Industry Median, 0 otherwise.

Question 2. Cash ROA

Cash ROA equals to Cash Flow from Operations divided by average Total Assets. It measures how well a company uses its asset to generate cash.

Score 1 if Cash ROA > Cash ROA Industry Median, 0 otherwise.

Question 3. CFO and Net Income

Score 1 if CFO > Net Income, 0 otherwise.

Earnings Predictability

Question 4. Earnings Variability

Earnings Variability is measured as the variance of a firm's ROA in the past five years.

Score 1 if Earnings Variability < Earnings Variability Industry Median, 0 otherwise.

Question 5. Sales Growth Variability

Sales Growth Variability is measured as the 5-year variance in sales growth.

Score 1 if Sales Growth Variability < Sales Growth Variability Industry Median, 0 otherwise.

Accounting Conservatism

Question 6. Research & Development Intensity

Research & Development Intensity is calcualted by Research & Development divided by the beginning Total Assets.

Score 1 if Research & Development Intensity > Research & Development Intensity Industry Median, 0 otherwise.

Question 7. CAPEX Intensity

CAPEX Intensity is calcualted by Capital Expenditure divided by the beginning Total Assets.

Score 1 if CAPEX Intensity > CAPEX Intensity Industry Median, 0 otherwise.

Question 8. Advertising Expenditure Intensity

Advertising Expenditure Intensity is calcualted by Advertising Expenditure divided by the beginning Total Assets. Note that Advertising Expenditure is not reported as a seperate line item for many companies, thus Selling, General, & Admin. Expense is used in this calculation.

Score 1 if Advertising Expenditure Intensity > Advertising Expenditure Intensity Industry Median, 0 otherwise.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note that all the Industry Median used for comparison in his original research, are substituted with Sector Median due to the limitation of data within certain countries.

Good or high score = 6, 7, 8
Bad or low score = 0, 1

Bellicum Pharmaceuticals has an G-score of 1. It is a bad or low score, which tends to have negative absolute returns.

Bellicum Pharmaceuticals  (OTCPK:BLCM) Mohanram G-Score Explanation

Partha Mohanram is the John H. Watson Chair in Value Investing at Rotman and the Acting Vice-Dean of Research Strategy and Resources.

In 2000, he wrote a research paper called "Separating Winners from Losers Among Low Book-to-Market Stocks Using Financial Statement Analysis".

This paper tests whether a strategy based on financial statement analysis of low book-to-market (growth) stocks is successful in differentiating between winners and losers in terms of future stock performance. Based on the research, a strategy based on buying high G-score (6, 7 or 8) firms and shorting low G-score (0 or 1) firms consistently earns significant excess returns. Further, the results do not support a risk based explanation for the book-to-market effect as the strategy returns positive returns in all years, and firms that ex-ante appear less risky have better future returns.

To conclude, one can use a modified fundamental analysis strategy (G-score) to identify mispricing and earn substantial abnormal returns.


Bellicum Pharmaceuticals Mohanram G-Score Related Terms

Thank you for viewing the detailed overview of Bellicum Pharmaceuticals's Mohanram G-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellicum Pharmaceuticals (Bellicum Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
3730 Kirby Drive, Suite 1200, Houston, TX, USA, 77098
Bellicum Pharmaceuticals Inc is a biopharmaceutical company that has discovered and developed novel, controllable cellular immunotherapies for various forms of cancer, including both hematological cancers and solid tumors. its proprietary Chemical Induction of Dimerization technology platform is designed to enable control of components of the immune system in real-time. Its product candidates are; BPX-601 an autologous GoCAR-T product candidate designed to treat solid tumors expressing prostate stem cell antigen, or PSCA, and BPX-603 an autologous dual-switch GoCAR-T product candidate designed to target solid tumors that express the human epidermal growth factor receptor 2 antigen, or HER2.
Executives
Charity Scripture officer: Chief Development Officer C/O BELLICUM PHARMACEUTICALS, INC., 3730 KIRBY DRIVE, STE. 1200, HOUSTON TX 77098
James M Daly director INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Stephen Davis director ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130
Charles S. Grass officer: Principal Accounting Officer C/O BELLICUM PHARMACEUTICALS, INC., 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Richard A. Fair director, officer: President and CEO C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
David Eric Strauss officer: Director, Corporate Controller 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Shane Ward officer: Sr. VP and General Counsel C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Woodard Jr Joseph Paul officer: SVP Clinical & Medical Affairs C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Aaron E. Foster officer: Sr VP, Head of Research C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE 800, HOUSTON TX 77030
Rosemary Y. Williams officer: Principal Accounting Officer 2130 W. HOLCOMBE BOULEVARD, SUITE 800, HOUSTON TX 77030
Judith V Klimovsky director C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Atabak Mokari officer: Sr. VP and CFO 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Jon P Stonehouse director 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
David M. Spencer officer: Chief Scientific Officer C/O BELLICUM PHARMACEUTICALS, INC., 2130 W. HOLCOMBE BLVD., STE. 800, HOUSTON TX 77030
Alan A Musso officer: CFO and Treasurer FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139